Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete regression of metastatic melanoma in a patient following open-heart surgery with an infective complication.

BMJ case reports·2026
Same author

A scalable, multi-resolution consensus clustering approach for prioritizing robust signals from high-throughput screens.

Briefings in bioinformatics·2026
Same author

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

The Journal of pathology·2026
Same author

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors.

Clinical & translational immunology·2026
Same author

Patient Views on a Pre-treatment Blood Test to Predict Outcomes Following PD-1 Inhibitor Therapy: A Qualitative Study.

International journal of behavioral medicine·2026

Related Experiment Video

Updated: Jun 6, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Kathleen I Pishas1, Fares Al-Ejeh, Irene Zinonos

  • 1Sarcoma Research Group, Discipline of Medicine, University of Adelaide and Hanson Institute Adelaide, South Australia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 25, 2010
PubMed
Summary

Nutlin-3a induces apoptosis in Ewing sarcoma cells by activating p53. This drug synergizes with standard chemotherapy, offering a new therapeutic strategy for Ewing sarcoma by targeting p53.

More Related Videos

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

Related Experiment Videos

Last Updated: Jun 6, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ewing sarcoma rarely harbors TP53 gene mutations, retaining functional wild-type p53.
  • This characteristic makes Ewing sarcoma a promising candidate for therapies targeting the p53 pathway.
  • MDM2 and MDM4 proteins inhibit p53 function.

Purpose of the Study:

  • To investigate the effects of Nutlin-3a, an MDM2 antagonist, on Ewing sarcoma cell lines.
  • To determine if Nutlin-3a can enhance the efficacy of existing Ewing sarcoma treatments.
  • To explore the role of p53 activation in Ewing sarcoma response to therapy.

Main Methods:

  • Assessed apoptosis and cell cycle arrest in Ewing sarcoma cell lines treated with Nutlin-3a.
  • Evaluated the combined effects of Nutlin-3a with MDM4 antagonists and standard chemotherapeutic agents.
  • Analyzed p53-dependent responses to Nutlin-3a exposure.

Main Results:

  • Nutlin-3a induced apoptosis in Ewing sarcoma cell lines with wild-type p53.
  • Nutlin-3a demonstrated synergistic cytotoxicity with vincristine, actinomycin D, doxorubicin, and etoposide.
  • Observed MDM4 protein overexpression in wild-type p53 Ewing sarcoma, suggesting a compensatory mechanism.

Conclusions:

  • p53-dependent apoptosis is the primary cellular response to Nutlin-3a in Ewing sarcoma.
  • Nutlin-3a shows potential for synergistic effects with current Ewing sarcoma chemotherapy regimens.
  • p53 activation represents a novel therapeutic strategy for Ewing sarcoma.